TRDA
TRDA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
4
$2.38M
Insider Sales
33
$20.13M
Total Volume
$22.51M
37 transactions
Net Activity
$17.75M
Net selling
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 89% of total transaction value.
- •Cluster buying: 3 unique insiders purchased shares, showing strong alignment.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Parmar Kush
Dir
$4.72M total
Mpm Bioventures 2018, L.P.
10%
$4.52M total
Mpm Bioventures 2014, L.P.
10%
$4.52M total
5Am Ventures V, L.P.
10%
$4.07M total
Baker Bros. Advisors LP
10%
$1.61M total
Quick Actions
TRDA has an insider buy conviction of 11%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at TRDA (TRDA) engaged in a total of 37 transactions reported via SEC Form 4 filings. Among these, 4 were open-market purchases and 33 were sales. The total volume of insider trading reached $22.51M.
The net insider activity for TRDA shows a net selling bias of $17.75M. This activity represents a 11% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Mpm Bioventures 2018, L.P. (10%), who traded 259.8K shares valued at $1.91M on Sep 4, 2026.
Entrada Therapeutics, Inc. (TRDA) Stock Price, News, Quote & History
New Analyst Forecast: $TRDA Given $13 Price Target
A rare muscle-disease drug candidate is designed for one dose every six weeks.
The Technical Signals Behind (TRDA) That Institutions Follow
TRDA - Entrada Therapeutics Inc Stock Price and Quote
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
FAQs About TRDA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for TRDA.